ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.908,54
1,33%
S&P 500
5.988,77
0,87%
Dow Jones
43.487,36
0,77%
Euro vs US Dollar
1,03276
0,25%
Bitcoin
103.880,49
3,87%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Longeveron Inc (LGVN) Börsenkurse

Longeveron Inc

Longeveron Inc (LGVN)

NASDAQ
1,73
-0,03
( -1,70% )
Aktualisiert: 16:09:15
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
1,73
Gebot
1,73
Fragen
1,74
Volumen
16.542
1,73 Tagesbereich 1,75
0,7707 52-Wochen-Bereich 11,00
Marktkapitalisierung
25,668M
Handelsende
1,76
Handelsbeginn
1,75
Letzte Trade
100
@
1.73
Letzter Handelszeitpunkt
16:09:15
Finanzvolumen
US$ 28.801
VWAP
1,7411
Durchschnittliches Volumen (3 Mio.)
451.880
Ausgegebene Aktien
14.836.775
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
0,00
Gewinn pro Aktie (EPS)
-
Erlöse
709k
Nettogewinn
-22,21M

Über Longeveron Inc

Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome ... Longeveron Inc is a biotechnology company developing cellular therapies for specific ageing-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and Hypoplastic left heart syndrome (HLHS). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
/www.longeveron.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Longeveron Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LGVN. The last closing price for Longeveron was US$1,76. Over the last year, Longeveron shares have traded in a share price range of US$ 0,7707 to US$ 11,00.

Longeveron currently has 14.836.775 shares in issue. The market capitalisation of Longeveron is US$26,11 million.

LGVN Neueste Nachrichten

Weitere Nachrichten

Form 4 - Statement of changes in beneficial ownership of securities

07 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Januar 2025
Edgar (US Regulatory)

Longeveron to Present at Biotech Showcase 2025

MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

18 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

12 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

12 November 2024
Edgar (US Regulatory)

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal...

12 November 2024
GlobeNewswire Inc.

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

11 November 2024
GlobeNewswire Inc.

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and...

04 November 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.08-4.419889502761.811.891.672068701.77597113CS
40.148.805031446541.592.241.593078561.83032147CS
12-0.37-17.6190476192.12.48431.594518802.01764091CS
26-2.46-58.71121718384.194.881.5911597142.97935672CS
52-8.57-83.203883495110.3110.770734557803.00219003CS
156-85.27-98.011494252987167.70.7707169907838.0275932CS
260-13.07-88.310810810814.84500.7707200423892.50123147CS

LGVN - Frequently Asked Questions (FAQ)

What is the current Longeveron share price?
The current share price of Longeveron is US$ 1,73
How many Longeveron shares are in issue?
Longeveron has 14.836.775 shares in issue
What is the market cap of Longeveron?
The market capitalisation of Longeveron is USD 26,11M
What is the 1 year trading range for Longeveron share price?
Longeveron has traded in the range of US$ 0,7707 to US$ 11,00 during the past year
What is the reporting currency for Longeveron?
Longeveron reports financial results in USD
What is the latest annual turnover for Longeveron?
The latest annual turnover of Longeveron is USD 709k
What is the latest annual profit for Longeveron?
The latest annual profit of Longeveron is USD -22,21M
What is the registered address of Longeveron?
The registered address for Longeveron is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Longeveron website address?
The website address for Longeveron is /www.longeveron.com
Which industry sector does Longeveron operate in?
Longeveron operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
NUKKNukkleus Inc
US$ 38,6119
(88,08%)
10,48M
VSVersus Systems Inc
US$ 2,8098
(46,34%)
52,05M
TGLTreasure Global Inc
US$ 0,308
(43,72%)
205,15M
ZEOZeo Energy Corporation
US$ 3,3099
(41,45%)
23,53M
BZAIBlaize Holdings Inc
US$ 8,85
(36,15%)
943,75k
BLRXBioLineRx Ltd
US$ 0,0924
(-24,20%)
14,97M
NRXPNRX Pharmaceuticals Inc
US$ 3,63
(-14,79%)
408,79k
PMAXPowell Max Ltd
US$ 0,713
(-14,08%)
1,92M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 3,85
(-13,09%)
7,98M
SPRCSciSparc Ltd
US$ 0,635449
(-11,74%)
503,34k
TGLTreasure Global Inc
US$ 0,3079
(43,68%)
205,27M
GCTKGlucoTrack Inc
US$ 0,0856
(15,99%)
169,73M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
83,33M
INTCIntel Corporation
US$ 21,155
(7,55%)
54,08M
VSVersus Systems Inc
US$ 2,8087
(46,29%)
52,07M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
LGVN
Longeveron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten